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Abstract.
Background: Emerging evidence indicates that the misfolded tau protein can propagate aggregates between cells in a prion-
like manner. This prion activity has been typically studied in brain extracts of patients with Alzheimer’s disease (AD), but
not in the olfactory region that can be a potential biomarker in AD.
Objective: To investigate the prion seeding activity of tau in nasal mucosa tissues using a cell culture model of tau propagation.
Methods: Brain and nasal mucosa homogenates were added to HEK293T cells expressing three repeat or four-repeat
domains of tau with the L266V, V337M (3RD∗VM) and P301L and V377M mutations (4RD∗LM) fused to the enhanced
green fluorescence protein (EGFP) respectively. We also measured the level of phosphorylated tau (p-tau), total tau (t-tau),
and p-tau/t-tau ratio and performed correlation analysis between tau prion activity and the level of tau.
Results: We found that brain and nasal tissue homogenates from patients with AD significantly induced tau aggregation
in HEK293T cells either expressing tau 3RD∗VM-EGFP or 4RD∗LM-EGFP compared with control brain and nasal tissue
homogenates. The levels of p-tau and p-tau/t-tau ratio were significantly increased in the brain of patients with AD; however,
no significant difference was found in nasal tissue compared with their respective control tissue homogenates.
Conclusion: These results suggest that the nasal tissues contain tau seeds, similar to the brain, albeit without changes in the
levels of p-tau and t-tau. Therefore, a cellular bioassay using nasal tissues would have great potential as an AD biomarker
because of the usefulness of nasal tissue biopsy.
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INTRODUCTION
According to the protein-only hypothesis, the
conformational change from a normal isoform
of a prion protein (PrPC) to a protease-resistant
pathogenic form called scrapie-type prion protein
(PrPSc) results in prion disease [1–3]. The common
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neuropathological feature of prion diseases is the pre-
dominantly extracellular accumulation of PrPSc in
the central nervous system [4]. PrPSc can propagate
from cell to cell (in vitro) and region to region in the
brain (in vivo) via the conversion of PrPC to PrPSc
[5, 6].
Tau is a microtubule-associated protein that forms
aggregates in the brain in a range of neurode-
generative diseases that are collectively known as
tauopathies. Previous studies have shown that tau
aggregates can propagate in a hierarchical manner
between synaptically connected neurons in the brain,
similar to a prion-like propagation [7–9]. A vari-
ety of tau seeds have been employed to study tau
propagation, e.g., brain extracts from patients with
tauopathy [10, 11] or tau transgenic mice [12, 13],
and cell lysates [14] or conditioned media [15, 16]
from cells bearing tau aggregates and recombinant
tau fibrils [17, 18]. Thus, the studies of tau propaga-
tion highlighted the use of cellular and animal models
for providing a platform to develop diagnostic and
therapeutic procedures [19].
We recently reported a significantly elevated level
of phosphorylated tau (p-tau) in nasal smears of
patients with Alzheimer’s disease (AD) compared
with age-matched, cognitively normal individuals
[20]. Phosphorylation is a major posttranslational
modification of tau and a key process in the formation
of tau aggregates [21–23]. Therefore, it is likely that
tau seeds with the ability to propagate tau aggregation
exist in the nasal tissues of these patients. However, it
is difficult to verify this hypothesis using biochemical
approaches, such as enzyme-linked immunosorbent
assay (ELISA). Conversely, cellular bioassays such
as the cellular models of tau propagation would help
verify the existence of tau seeds in the nasal cavity
of patients with AD. Here, we investigated the prion
seeding activity of the extracts from the nasal autopsy
tissues of patients with AD. The results of this study
suggest that a cellular bioassay using nasal tissues has
a great potential as an AD biomarker because of the
usefulness of nasal tissue biopsy.
MATERIALS AND METHODS
Human postmortem tissues
This study complies with the Declaration of
Helsinki and was approved by the Ethics Committee
of Shiga University of Medical Science (reference
number, R2019-102). Postmortem nasal mucosa and
Table 1
Braak stage and demographic data of control subjects and patients
with AD
Characteristics Control AD PiD
n 10 10 1
Sex Male 7 Male 2
Female 3 Female 8 Female
Age (y)∗ 77.6 ± 9.2 81.9 ± 4.29 75
Braak stage I–II VI –
∗mean ± SEM.
brain tissues from patients with Pick’s disease (PiD)
(n = 1), patients with AD (n = 10), and normal sub-
jects (n = 10) were obtained from the Fukushimura
Brain Bank, Choju Medical Institute of Fukushimura
Hospital, Toyohashi, Japan. The tissues were col-
lected with patient consent and protocols were appr-
oved by the Ethics Committee of Fukushimura
Hospital. The Braak stage and demographic infor-
mation of the postmortem tissues used in this study
are summarized in Table 1.
Preparation of tissue homogenates
Fresh tissues were cut, weighed, and homogenized
in calcium- and magnesium-free DPBS (Nacalai
Tesque, Kyoto, Japan) (40 mL/g of wet weight) using
a hand-held micro homogenizer (model, NS-310EII;
Microtec, Chiba, Japan), aliquoted at 50 L/tube, and
kept at −80◦C until use. Prior to the cell aggrega-
tion assay, the brain homogenate was sonicated on
ice for 60 s using a sonicator (model, XL2020; Mis-
onix, New York, NY, USA) and diluted with DPBS
to a concentration of 6%.
Plasmid construction
Full-length tau (0N3R/0N4R) was cloned into
the pcDNA3.1 vector from the human neuroblas-
toma cell line SH-SY5Y cDNA. Two site-directed
mutations were introduced in the construct encod-
ing the three repeat domains (3RD) of tau (amino
acids 243 to 274 and 306 to 375, corresponding
to 2N4R tau) and four-repeat domains (4RD) of
tau (amino acids 243 to 375, corresponding to 2N-
4R tau) using a QuikChange Lightning Multi Site-
Directed Mutagenesis Kit (Agilent Technologies,
CA, USA). The primers employed to introduce the
mutations were designed using the website pro-
vided (www.agilent.com/genomics/qcpd); the primer
details as listed in Table 2. The 3RD of tau construct
with the L266V and V337M mutations (3RD∗VM)
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Table 2
Sequences of the primers used to introduce mutations in the tau
3RD and 4RD gene
Primer sequence Mutation
(site of mutation was bold)
5′-gctccactgagaacg Leucine (L) to Valine
tgaagcaccagccg-3′ (V): ctg to gtg
5′-tatcaaacacgtcct Proline (P) to leucine
gggaggcggcagtg-3′ (L): ccg to ctg
5′-aaccaggaggtggccaga Valine (V) to Methionine
tggaagtaaaatctgag-3′ (M): gtg to atg
and 4RD of tau construct with the P301L and
V337M mutations (4RD∗LM) was then fused to the
enhanced green fluorescence protein (EGFP) at the
C terminus using a 20-amino-acid flexible linker
(KKIETHKSTVPRARDPPVAT). This construct was
then introduced into the pIRESpuro3 vector (Clon-
tech, CA, USA) and was termed 3RD∗VM-EGFP and
4RD∗LM-EGFP.
Development of stable cell lines
HEK293T cells were cultured in Dulbecco’s Mod-
ified Eagle’ Medium (DMEM; Nacalai Tesque)
supplemented with 10% (vol/vol) fetal bovine serum
(FBS; Hyclone, UT, USA) and 1% (vol/vol) peni-
cillin/streptomycin (Nacalai Tesque); this culture
medium was termed complete culture medium
(CCM). Cultures were maintained in a humidified
atmosphere of 5% (vol/vol) CO2 at 37◦C. Cells
were plated in a 24-well plate at a density 1 × 105.
After 24 h of culture, cells were transfected with the
3RD∗VM-EGFP or 4RD∗LM-EGFP plasmid using
Lipofectamine 2000 (Invitrogen, MA, USA). At 48 h
post-transfection, cells were trypsinized and trans-
ferred to a 10 cm2 culture dish, followed by the
selection of stable polyclonal cells in CCM contain-
ing 1 g/mL puromycin (Nacalai Tesque) for 7 days.
Monoclonal cells were generated via limiting dilution
of the polyclonal cell population in a 96-well plate.
Validation of protein expression in HEK293T
cells stably expressing tau 3RD∗VM-eGFP
Stable monoclonal cells cultured in 6-well plates
were washed with cold DPBS twice. Cells were
scraped with 100 L of RIPA buffer (Nacalai Tesque)
and the cell lysates were transferred to a new micro-
centrifuge tube. The tube was incubated on ice for
30 min and centrifuged at 10,000 × g for 10 min at
4◦C. The supernatant was collected into a new tube
and protein concentration was determined using a
BCA Protein Assay Kit (Nacalai Tesque). Proteins
(10 g) in 4 × sample buffer and 10 × reducing
buffer (Life Technologies, MA, USA) were denatured
at 95◦C for 10 min, applied to the lanes of precast
15% polyacrylamide gels (Wako Pure Chemicals,
Osaka, Japan), electrophoresed, and transferred to
polyvinylidene difluoride membranes (Immobilon-
P; Merck Millipore, MA, USA). The membranes
were blocked with 5% skim milk in Tris-buffered
saline containing 1% Tween 20 (TBST) at room
temperature for 1 h, followed by incubation at 4◦C
with the following primary antibodies: 3 days with
a mouse monoclonal antibody against the tau three-
repeat or four-repeat isoform (clone 8E/C11 or clone
1E1/A6; 1:1000; Merck Millipore), overnight with a
mouse monoclonal antibody against -actin (1:5000;
Santa Cruz Biotechnology, CA USA), and overnight
with a rabbit polyclonal anti-GFP antibody (1:1000;
Merck Millipore). The membranes were washed three
times with TBST (10 min each time) and then incu-
bated at room temperature for 1 h with the following
secondary antibodies: goat anti-mouse IgG or goat
anti-rabbit IgG labeled with horseradish peroxidase
(1:20000; Jackson ImmunoResearch Laboratories,
PA, USA). After three further washes with TBST, the
membranes were reacted with an enhanced chemilu-
minescent substrate (SuperSignal West Pico, Thermo
Fischer Scientific, MA, USA), and proteins were then
detected using an ImageQuant LAS 4000 mini system
(GE Healthcare Life Science, Chicago, IL, USA).
Cell aggregation assay
Cells were plated onto 96-well plates with a
clear bottom and black polystyrene walls (Greiner,
Kremsmunster, Austria) at a density 25,000 cells
per well using CCM containing 0.1 g/mL Hoechst
33258 (Life Technologies). Cells were incubated
overnight at 37◦C in a humidified atmosphere of
5% CO2, to allow adherence to the plate. Brain
homogenates (10% final volume) were premixed with
Lipofectamine 2000 (2% final volume) (Invitrogen)
in Opti-MEM (88% final volume) (Gibco, Life Tech-
nologies) at room temperature for 2 h, followed by
the addition of 10 L of the brain homogenates to
the cells. Plates were then incubated at 37◦C in a
humidified atmosphere of 5% CO2 for 4 days. The
prion seeding activity of the extracts was measured
by fluorescence intensity using a microplate reader
(Tecan Infinite M200, Mannedorf, Switzerland) at
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an excitation wavelength of 385 nm and an emission
wavelength of 530 nm and normalized with the num-
ber of cells. The percentage of cells with aggregates
was calculated from the image at five different regions
for each sample. Cell imaging was performed on
an inverted fluorescence microscope (model, IX83;
Olympus, MA, USA) using the channels of both the
DAPI (excitation: 352 nm; emission: 461 nm) and
FITC (excitation: 495 nm; emission: 519 nm).
Immunocytochemistry
ELISA
For ELISA analysis, brain and nasal tissues were
homogenized in a 50-fold homogenization buffer
(50 mM Tris HCL buffer, pH 8.0, 8 M guani-
dine HCl, 200 mM NaCl, 2 mM EDTA, and 0.05%
n-dodecyl--d-maltoside for 1 min using a homoge-
nizer (Physcotron NS-310E11; Microtec) and were
stored at −80◦C until use. The homogenates were
thawed and mixed well, and then centrifuged at
14,000 × g for 20 min at 25◦C. Subsequently, the
supernatants (90 l) were filtered with Sephadex G-
10 (GE Healthcare Life Science) set in a Bio-Spin
Chromatography Column (Bio-Rad Laboratories)
by centrifugation at 800 × g for 1 min at 25◦C,
to remove guanidine HCl. After the total protein
concentration was determined using a Pierce BCA
Protein Assay Kit (ThermoFisher Scientific), total
tau (t-tau) and phosphorylated tau (pT181) were
measured in triplicate using commercially available
kits (KHB0042 and KHO0631, respectively; Ther-
moFisher Scientific), according to manufacturer’s
instructions. Optical density at 450 nm in each well
was measured using a microplate reader (Infinite
M200; Tecan, Männedorf, Switzerland).
Statistical analysis
Data pertaining to fluorescence/cells or % cells
with aggregates are presented as the mean ± SEM.
The values represent the average of 10 patient sam-
ples per group, with the exception of the AD Nasal
group, which included nine patients (five images of
the samples of each patient were averaged). Data col-
lected from ELISA also presented as mean ± SEM.
The values represent the averages of 10 patient sam-
ples per group. Statistical comparisons between two
groups were performed using Student’s t-test for
single comparisons and the Kruskal−Wallis test fol-
lowed by Dunn’s test for multiple comparisons. Pairs
of nonparametric variables (fluorescence/cell, % cells
with aggregates, and p-tau/t-tau ratio) were then
tested using a Spearman linear correlation model. Sta-
tistical analyses were performed using the PRISM 8
software (GraphPad Software, CA, USA). The statis-
tical significance of all tests was set at p < 0.05.
RESULTS
Development of a cellular bioassay using the
stable cell model expressing tau 3RD∗VM-EGFP
or 4RD∗LM-EGFP
The present cellular bioassay system was devel-
oped for the determination of prion seeding activity in
the brain and nasal tissue homogenates from control
subjects and patients with AD. In this study, we devel-
oped a stable cell line expressing tau 3RD∗VM-EGFP
or 4RD∗LM-EGFP. Several clones were selected to
validate the protein expression of tau 3RD or 4RD in
this cell line. Western blot data showed a significant
protein band between 37 and 50 kDa corresponding
to tau 3RD tagged EGFP in clones 2, 3, and 5 which
represent the HEK293T cell line transfected with the
3RD∗VM-EGFP plasmid (Fig. 1a). A significant pro-
tein band between 37 and 50 kDa corresponding to
tau 4RD tagged EGFP in clones 1, 2, and 3 was also
expressed in HEK293T cells expressing 4RD∗LM-
EGFP (Fig. 1b); whereas the HEK293T cell line
transfected with vector plasmid (EGFP without tau)
showed only a protein band for GFP at 25 kDa, with
no protein band for tau 3RD or 4RD (Fig 1a, b),
suggesting that the transfection of 3RD∗VM-EGFP
or 4RD∗LM-EGFP constructs into HEK293T cells
increased tau 3RD or 4RD tagged EGFP expression.
The cell culture system was then tested using
tau seeds from brain tissue homogenates isolated
from control and patient with AD or PiD. The
results showed that both AD and PiD brain tissue
homogenates induced significant tau aggregation
(Fig. 2a) and showed increased fluorescence per
cell compared to control L2000 and control brain
homogenates in cells expressing tau 3RD*VM-EGFP
(Fig. 2b). However, only brain tissue homogenates
from AD patients showed significant tau aggre-
gation (Fig. 2c) and increased in fluorescence per
cell compared to control L2000 and control brain
homogenates in cells expressing tau 4RD*LM-EGFP
(Fig. 2d). The same method was then used to examine
the tau prion activity in the nasal tissue homogenates.
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Fig. 1. Development of a cellular model of tau propagation. Validation of (a) 3RD∗VM-EGFP and (b) 4RD∗LM-EGFP expression. Stable
cells transfected with vector plasmid (V) and three stable selected clones (clone 2 (C2), clone 3 (C3), and clone 5 (C5) in 3RD∗VM-EGFP
and C1, C2, and C3 in 4RD∗LM-EGFP) were probed with anti-tau three- or four-repeat isoforms (3RD or 4RD), anti-GFP, and anti--actin
antibodies on separate membranes. A protein ladder (M) was used as a size reference. Representative images of HEK 293T cells expressing
(c) 3RD∗VM-EGFP and (d) 4RD∗LM-EGFP. Scale bar = 20 m.
Fig. 2. Development of tau seed assay in cellular model of tau propagation. Representative images of HEK 293T cells expressing (a)
3RD∗VM-EGFP and (c) 4RD∗LM-EGFP incubated with L2000 or seeded with crude brain homogenates from control, AD, and PiD
subjects for 4 days. Scale bar = 50 m. Quantification of tau aggregation (fluorescence/cell) in HEK293T cells expressing (b) 3RD∗VM-
EGFP and (d) 4RD∗LM-EGFP. Data are presented as the mean ± SEM measured from five replicates for each group (one sample per group).
∗p < 0.05, ∗∗p < 0.001.
Tau prion activity was significant in the brain
and nasal tissue homogenates from patients with
AD in HEK 293T cells expressing
3RD∗VM-EGFP or 4RD∗LM-EGFP
To test the tau prion activity, cells expressing tau
3RD∗VM-EGFP or 4RD∗LM-EGFP were seeded
with the brain or nasal tissue homogenates from con-
trols and patients with AD. We found that brain and
nasal tissue homogenates isolated from patients with
AD significantly induced tau aggregate formation
in HEK293T cells expressing tau 3RD∗VM-EGFP
(Fig. 3a). Statistical analysis showed that the brain
and nasal tissue homogenates from samples of
patients with AD significantly increased the fluores-
cence per cell compared with the brain and nasal
tissue homogenates from control samples (Fig. 3b).
The percentage of cells with aggregates also signif-
icantly increased when seeded with the brain and
nasal tissue homogenates from samples from AD
patients compared with the brain and nasal tissue
homogenates from control samples (Fig. 3c). A sim-
ilar observation was also apparent in HEK 293T
cells expressing tau 4RD∗LM-EGFP (Fig. 4a-c).
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Fig. 3. HEK 293T cells stably expressing tau 3RD*VM-EGFP detect tau prions in the brain and nasal tissue homogenates from patients
with AD. Brain and nasal tissue homogenates from control and AD patient samples were diluted in DPBS and incubated for 4 days with
3RD*VM-EGFP-expressing cells. a) Representative images of HEK 293T cells expressing 3RD*VM-EGFP seeded with the brain and nasal
tissue homogenates from control individuals and patients with AD. Scale bar = 50 m. Quantification of tau aggregation by (b) fluorescence
per cell. Data are presented as the mean ± SEM measured from 10 samples per group, with the exception of AD nasal homogenates, for
which nine samples were used, and (c) percentage of cells with aggregates. Data are presented as the mean ± SEM measured from five
images for each sample. ∗p < 0.05, ∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Fig. 4. HEK 293T cells stably expressing tau 4RD∗LM-EGFP detect tau prions in the brain and nasal tissue homogenates from patients
with AD. The same methods were applied as those described for HEK293T cells stably expressing tau 3RD∗VM-EGFP. a) Representative
images of HEK 293T cells expressing 4RD∗LM-EGFP seeded with the brain and nasal tissue homogenates from control individuals and
patients with AD. Scale bar = 50 m. Quantification of tau aggregation by (b) fluorescence per cell. Data are presented as the mean ± SEM
measured from ten samples per group, with the exception of AD nasal homogenates, for which nine samples were used, and (c) percentage
of cells with aggregates. Data are presented as the mean ± SEM measured from five images for each sample. ∗∗p < 0.001, ∗∗∗∗p < 0.0001.
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These results suggest that both brain and nasal tis-
sue homogenates from patients with AD contain tau
prions.
The level of phosphorylated tau was increased
and the level of total tau was decreased in the
brain tissue homogenates, with no changes
observed in the nasal tissue homogenates of
patients with AD
To validate the dependency of prion activity in the
brain and nasal tissue homogenates on the level of
p-tau, total tau (t-tau), an ELISA was carried out.
We found that the levels of p-tau and t-tau in the
brain tissue homogenates of patients with AD were
significantly increased and decreased compared with
control brain tissue homogenates respectively; there-
fore, the ratio of p-tau to t-tau (p-tau/t-tau ratio) in
the brain tissue homogenates of patients with AD was
significantly increased (Fig. 5a-c). In contrast, there
was no significant difference in the levels of p-tau and
t-tau and in the p-tau/t-tau ratio between the nasal tis-
sue homogenates from patients with AD and controls
(Fig. 5d-f). These results suggest that, although the
nasal tissues exhibited prion activity, similar to the
brain tissues, no changes observed in the levels of
p-tau and t-tau in the nasal tissues.
The tau prion activity in the nasal tissue
homogenates was not associated with the tau
prion activity in the brain tissue homogenates
To determine the relationship between the tau prion
activity in the nasal and brain tissue homogenates,
we performed a correlation analysis. We found no
significant correlation between the level of p-tau, t-
tau, or p-tau/t-tau in the brain tissue homogenates
and the level of p-tau, t-tau or p-tau/t-tau in the nasal
tissue homogenates (Fig. 6a-c). Moreover, we also
observed no significant correlation between the tau
prion activity in the brain tissue homogenates and
the tau prion activity in the nasal tissue homogenates
in 3RD∗VM-EGFP (Fig. 6d, e) or 4RD∗LM-EGFP
(Fig. 6f, g), measured by the fluorescence per cell or
percentage of cells with aggregates.
The tau prion activity was associated with the
p-tau/t-tau ratio in the brain tissue homogenates
We further examined our data by performing a cor-
relation analysis between tau prion activity and the
level of tau in the nasal or brain tissue homogenates.
In tau 3RD∗VM-EGFP-expressing cells seeded with
the brain samples, the tau prion activity (measured by
fluorescence per cell) was strongly positively corre-
lated with the p-tau/t-tau ratio levels in the AD group
(Pearson’s r = 0.7781, p = 0.0080) (Fig. 7a). However,
the prion activity (measured by percentage of cells
with aggregates) did not show correlation with the
p-tau/t-tau ratio (Fig. 7b). There was no correlation
between the tau prion activity measured by fluores-
cence per cell or percentage of cells with aggregates
and the level of p-tau/t-tau ratio in tau 3RD∗VM-
EGFP-expressing cells seeded with the nasal samples
(Fig. 7c, d). Similar results were found for the tau
4RD∗LM-EGFP-expressing cells seeded with the
brain samples from patients with AD. The tau prion
activity measured by fluorescence per cell (Pear-
son’s r = 0.7162, p = 0.0198) and percentage of cells
with aggregates (Pearson’s r = 0.8545, p = 0.0016)
had positive correlations with the p-tau/t-tau ratio
(Fig. 7e, f). No correlation was observed between the
tau prion activity and the p-tau/t-tau in tau 4RD∗LM-
EGFP-expressing cells seeded with the nasal samples
(Fig. 7g, h). These results suggest that an imbalance
between p-tau and t-tau, indicated by the high ratio
of p-tau/t-tau, may predict an increase in tau prion
activity in the brain but not in the nasal tissues of AD
patients. Nevertheless, our study shows that the nasal
tissues contain tau seeds and was propagated in the
tau model of cellular bioassay in a similar way to the
brain tissues from AD patients.
DISCUSSION
This study investigated the prion seeding activity of
the nasal tissue homogenates using cell culture model
of tau propagation. The nasal tissue homogenates, as
well as the brain tissue homogenates, from patients
with AD significantly induced the aggregation of tau
compared with control tissue homogenates. In con-
trast, there was no significant difference in the levels
of p-tau, t-tau and in the p-tau/t-tau ratio between
the nasal tissue homogenates from patients with AD
and control subjects. These results suggest that cellu-
lar bioassay using nasal tissues has great potential as
an AD biomarker because of the usefulness of nasal
tissue biopsy.
Initially, we developed HEK293T cells stably
expressing tau 3RD∗VM-EGFP or 4RD∗LM-EGFP
as cellular bioassay system and tested both cell types
using the brain samples from control, AD, and PiD
subjects, to establish the method. The results of
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Fig. 5. Determination of the levels of (a, d) p-tau and (b, e) t-tau and (c, f) the p-tau/t-tau ratio by ELISA in (a–c) the brain homogenates and
(d–f) the nasal homogenates. Data are presented as the mean ± SEM measured from triplicate experiments for each sample, with 10 samples
per group. ∗∗p < 0.01, ∗∗∗p < 0.001.
this experiment showed that the AD and PiD brain
samples alone induced tau aggregates in HEK293T
cells stably expressing tau 3RD∗VM-EGFP, indicat-
ing that both the AD and PiD brain samples contained
tau prions. However, only brain samples from AD
patients significantly induced tau aggregation in HEK
293T cells stably expressing tau 4RD∗LM-EGFP.
Previous studies showed that the Pick bodies that
are present in PiD typically consist of the three
repeat (3R) tau isoform [24], whereas the neurofib-
rillary tangles observed in AD exhibit aggregation
of both the 3R and four repeat (4R) isoforms [25,
26]. Similar to our result, Woerman et al. [11] also
demonstrated that the tau seeds extracted from a
PiD brain infected HEK293T cells expressing tau
3RD∗VM tagged with the yellow fluorescence pro-
tein (YFP), as indicated by the formation of tau
aggregates. However, the tau seeds extracted from
an AD brain were unable to infect the same cells
or cells expressing tau 4RD∗LM-YFP; rather, tau
aggregation occurred only in HEK293T cells express-
ing tau (3RD∗VM,4RD∗LM)-YFP [11]. In contrast,
Sanders et al. [14] showed that the tau seeds
extracted from PiD or AD brains were able to infect
HEK293T cells expressing tau 4RD(wild type)-YFP.
The discrepancy of these findings may be due to
the differences in the methods used. The crude
homogenates and not the specific tau fibrils isolated
from the brain and cell system in expressing only the
repeat domains of tau, not the full length of tau, was
used to test the tau prion seeding activity in the present
study. Conclude that different samples with the same
disease might contain distinct 3R and 4R prions and
that different panel of cells might have different sen-
sitivity regarding the detection of the presence of tau
prions.
Based on the same experimental approach, we then
tested the cell system developed in this study using the
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Fig. 6. Correlation analysis to determine the dependency of the measured parameters in the brain and nasal samples. a) Correlation analysis
of the level of p-tau. b) Correlation analysis of the level of t-tau. c) Correlation analysis of the p-tau/t-tau ratio. d, e) Correlation analysis
of the prion seeding activity measured as fluorescence per cell or percentage of cells with aggregates in HEK 293T cells stably expressing
tau 3RD∗VM-EGFP. f, g) Correlation analysis of the prion seeding activity measured as fluorescence per cell or percentage of cells with
aggregates in HEK 293T cells stably expressing tau 4RD∗LM-EGFP. There were no correlations in the changes of tau levels and prion
seeding activity between the brain and nasal tissue homogenates.
Fig. 7. Correlation analysis in HEK 293T cells stably expressing tau (a–d) 3RD∗VM-EGFP and (e–h) 4RD∗LM-EGFP for the determination
of the dependency of the prion seeding activity measured as fluorescence per cell or percentage of cells with aggregates and the level of
p-tau/t-tau ratio in the (a, b, e, f) brain samples and (c, d, g, h) nasal samples. The prion seeding activity measured as fluorescence per cell
was significantly correlated with the p-tau/t-tau ratio only in the brain samples.
brain and nasal samples from patients with AD. We
found that the nasal tissue homogenates from patients
with AD induced tau aggregation in HEK293T cells
stably expressing tau 3RD∗VM-EGFP or 4RD∗LM-
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EGFP, similar to the brain tissue homogenates from
the same patient samples, thus indicating the pres-
ence of tau prion activity in the nasal and brain
tissue homogenates from patients with AD. How-
ever, the levels of p-tau and the p-tau/t-tau ratio, as
assessed by ELISA, were significantly elevated in the
brain tissue homogenates but remained unchanged
in the nasal tissue homogenates compared with their
respective controls. In contrast with our findings, a
previous preliminary study of 25 AD subjects among
whom 20 individuals exhibited an olfactory impair-
ment reported that the levels of t-tau and p-tau in
the nasal secretion were significantly higher com-
pared with the control [27]. Our previous study of
25 AD subjects also showed significant changes in
the t-tau and p-tau levels, and, consequently, a high
p-tau/t-tau ratio in the nasal cavity compared with
age-matched controls when measured using meth-
ods with high sensitivity, such as pre-treatment of
the nasal samples with guanidine-n-dodecyl-beta-d-
maltoside (PGD) prior to detection by ELISA [20].
The significant changes in the level of tau in nasal
samples were not observed in our study, probably
because of differences in the properties of the sam-
ples used here, as the nasal mucosa was obtained
from autopsy rather than biopsy. The difference in
the sample processing prior to ELISA would also
contribute to these discrepancies. The small num-
ber of samples (n = 10) and low sensitivity of the
ELISA method used here might also have contributed
to this poor level of significant differences. Never-
theless, the cellular bioassay confirmed the presence
of tau prions in the nasal homogenates, similar to
the brain, thus suggesting an alternative potential
method for measuring AD biomarkers using nasal
tissue biopsy.
In the present study, we prepared brain extracts
using a unique method that was optimized for the
nasal swab in our previous study [20], which showed
that there are decreased levels of total tau in the AD
brain. A number of studies have reported the lev-
els of total tau in AD brains; however, discrepancies
exist among the results of these studies. For exam-
ple, decreased levels of total tau were observed in
detergent-free extracts of AD brains [28, 29], whereas
several studies have reported increased levels of total
tau in the extracts with and without detergents from
AD brains [30–32]. Furthermore, other studies have
reported differences in changes of the levels of total
tau between the brain regions of AD brains [33–35].
According to these findings, it is likely that the lev-
els of total tau in the AD brain would depend on the
extraction procedures and the brain regions, which
might seem puzzling. In the last decade, most cases
of AD were associated with olfactory dysfunction,
which is characterized as an early marker of AD [36].
A study of 60 patients with AD reported that the olfac-
tory dysfunction was correlated with the cognitive
levels and, thus, might be an indicator of pathologi-
cal cognitive decline [37]. In addition, the olfactory
bulb and olfactory projection area in patients with AD
were associated with the neurotic changes of the tau
protein [38]; moreover, the olfactory tau was highly
significantly correlated with neuritic Braak staging
in the brain [38, 39]. These findings led us to raise
the question of whether a relationship exists between
the tau level or tau prions detected in the brain and the
nasal mucosa of patients with AD. However, we failed
to observe any relationship between these parameters,
perhaps because of the small sample size. Never-
theless, we found a significant relationship between
the tau prions activity and the p-tau/t-tau ratio in the
brain, indicating that tau prions might be predictive
on the imbalance between p-tau and t-tau.
In addition to the small number of samples, this
study had other limitations. First, the cell system used
in this study was focused on cells expressing either the
tau 3R or 4R isoform. The cell system co-expressing
both 3R and 4R was not measured. This may provide a
better reflection of the cellular bioassay system as the
AD brain exhibits aggregation of both tau isoforms.
Second, crude homogenates, and not the specific tau
fibrils isolated from the brain, were used to test the
tau prion seeding activity. Third, the tau aggregation
measured in this study was limited to the fluorescence
intensity and the counting of cells with tau puncta
in the cell imaging with no further validation of the
biochemical properties of the tau aggregates formed
in the cells. This is because the cell system in this
study was expressing only the repeat domains of tau,
not the full length of tau. There are limited avail-
able antibodies that recognize p-tau within the repeat
domains of tau; therefore, these cell systems are not
validated to quantify tau aggregation in living cells.
Finally, characterization of the nasal-induced aggre-
gates is a critical issue to validate prion activity in
the nasal tissues; however, further characterization
of nasal prions is left for future work.
In conclusion, our results suggest that a cellular
bioassay using nasal tissues has great potential as
an AD biomarker because of the usefulness of nasal
tissue biopsy and would provide an important con-
tribution to the development of ex vivo diagnosis
method for AD using the nasal tissues.
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